Methylprednisolone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Anti-inflammatory or immunosuppressive Initial: 2-60 mg/day, depending on the disease being treated. Allergic conditions 24 mg on day 1; 20 mg on day 2; 16 mg on day 3; 12 mg on day 4; 8 mg on day 5; 4 mg on day 6. All doses to be given as a single or in divided doses. IV As methylprednisolone Na succinate: Anti-inflammatory or immunosuppressive 10-500 mg/day. Acute allograft rejection in organ transplant recipients 0.5-1 g/day. Status asthmaticus 40 mg, repeated according to patient's response. IM Anti-inflammatory or immunosuppressive As methyprednisolone Na succinate: 10-80 mg once daily. As methylprednisolone acetate: 10-80 mg every 1-2 wk. Intra-articular Anti-inflammatory or immunosuppressive As methylprednisolone acetate: 4-10 mg (small joints); 10-40 mg (medium joints); 20-80 mg (large joints). May be repeated every 1-5 wk. Intralesional Anti-inflammatory or immunosuppressive As methylprednisolone acetate: 20-60 mg every 1-5 wk. Corticosteroid-responsive dermatoses As methylprednisolone acetate: 20-60 mg, may repeat up to 4 inj at intervals depending on the type of lesion and patient's response to the initial inj. Topical Corticosteroid-responsive dermatoses As 0.1% methylprednisolone aceponate oint, cream or lotion: Apply thinly to affected area once daily for up to 12 wk.
Administration
Should be taken with food.
Contraindications
Systemic fungal infections unless specific anti-infective therapy is employed; IM admin in idiopathic thrombocytopenic purpura. Intrathecal admin. Concurrent admin of live or live, attenuated vaccines (in patients receiving immunosuppressive doses).
Special Precautions
Patient w/ heart failure, HTN, DM, GI disease (e.g. diverticulitis, intestinal anastomoses, peptic ulcer, ulcerative colitis), multiple sclerosis, myasthenia gravis, acute MI, cataracts, glaucoma, osteoporosis, history of seizure disorder, thyroid disease. Avoid abrupt withdrawal. Renal and hepatic impairment (including cirrhosis). Childn. Pregnancy and lactation. Monitoring Parameters Monitor BP, blood glucose, electrolytes, growth in childn.
Adverse Reactions
Adrenal suppression, anaphylactoid reactions, immunosuppression, acute myopathy, Kaposi's sarcoma, psychiatric disturbances (e.g. depression, euphoria, insomnia, mood swings, personality changes), increased susceptibility and severity of infections, impaired healing, HTN, Na and fluid retention, CV collapse (high dose), peptic ulcer, cataract subcapsular, skin atrophy, acne, muscular weakness, growth retardation, decreased blood K; dermal/subdermal skin depression at inj site. Topical: Itching, burning erythema, vesiculation; rarely, folliculitis, hypertrichosis, perioral dermatitis, skin discolouration, allergic skin reactions.
Drug Interactions
Loss of corticosteroid-induced adrenal suppression w/ aminoglutethimide. Risk of hypokalaemia w/ K-depleting agents (e.g. amphotericin B, diuretics). Decreased clearance w/ macrolide antibiotics. May decrease serum levels of isoniazid. Increased clearance w/ cholestyramine. Risk of convulsions w/ ciclosporin. Increased risk of arrhythmias w/ digitalis glycosides. Decreased metabolism w/ oestrogens, including OCs. Enhanced metabolism w/ CYP3A4 inducers (e.g. rifampicin, barbiturates). Increased plasma concentrations w/ CYP3A4 inhibitors (e.g. ketoconazole, erythromycin). Risk of GI effects w/ aspirin or other NSAIDs. May increase the anticoagulant effect of warfarin. May reduce the therapeutic effect of antidiabetics.
ATC Classification
D07AA01 - methylprednisolone ; Belongs to the class of weak (group I) corticosteroids. Used in the treatment of dermatological diseases.
H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
D10AA02 - methylprednisolone ; Belongs to the class of topical corticosteroids used in the treatment of acne.
Disclaimer: This information is independently developed by CIMS based on methylprednisolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in